Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets

US$ in thousands

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	2,730,000)	3,105,900)	2,885,600)	2,193,700)	1,617,800)
Marketable securities	8,114,800)	4,636,400)	2,809,100)	1,393,300)	1,596,500)
Accounts receivable, net	5,667,300)	5,328,700)	6,036,500)	4,114,700)	2,672,200)
Inventories	2,580,500)	2,401,900)	1,951,300)	1,916,600)	1,415,500)
Prepaid expenses and other current assets	386,600)	411,200)	332,400)	160,800)	387,100)
Current assets	19,479,200)	15,884,100)	14,014,900)	9,779,100)	7,689,100)
Marketable securities	5,396,500)	6,591,800)	6,838,000)	3,135,600)	3,256,800)
Property, plant, and equipment, net	4,146,400)	3,763,000)	3,482,200)	3,221,600)	2,890,400)
Intangible assets, net	1,038,600)	915,500)	6,700)	—)	—)
Deferred tax assets	2,575,400)	1,723,700)	876,900)	858,900)	824,200)
Other noncurrent assets	444,100)	336,400)	216,100)	168,100)	144,700)
Noncurrent assets	13,601,000)	13,330,400)	11,419,900)	7,384,200)	7,116,100)
Total assets	33,080,200)	29,214,500)	25,434,800)	17,163,300)	14,805,200)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Regeneron Pharmaceuticals Inc. current assets increased from 2021 to 2022 and from 2022 to 2023.
Property, plant, and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Regeneron Pharmaceuticals Inc. property, plant, and equipment, net increased from 2021 to 2022 and from 2022 to 2023.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Regeneron Pharmaceuticals Inc. noncurrent assets increased from 2021 to 2022 and from 2022 to 2023.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Regeneron Pharmaceuticals Inc. total assets increased from 2021 to 2022 and from 2022 to 2023.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Regeneron Pharmaceuticals Inc. cash and cash equivalents increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Marketable securities	Amount of investment in marketable security, classified as current.	Regeneron Pharmaceuticals Inc. marketable securities increased from 2021 to 2022 and from 2022 to 2023.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Regeneron Pharmaceuticals Inc. accounts receivable, net decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Regeneron Pharmaceuticals Inc. inventories increased from 2021 to 2022 and from 2022 to 2023.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items